title: Pharmacologic treatment strategies for sexual dysfunction in patients with epilepsy and depression.
abstract: Sexual dysfunction is a frequently encountered comorbid condition in patients with many medical and psychiatric conditions, such as epilepsy and depression. Most depressed patients experience some type of sexual dysfunction, decreased sexual desire being the most common. The association of sexual dysfunction with epilepsy is less clear. Changes in sex hormone levels are common in patients with epilepsy and may be attributable to the disease or to antiepileptic drugs (AEDs). Sexual dysfunction associated with depression or epilepsy is generally treated according to standard guidelines for the management of sexual disorders, since data from special populations are not available. The most common forms of female sexual dysfunction are lack of sexual desire and difficulty achieving orgasm. There are no approved pharmacotherapies for female hypoactive sexual desire disorder or female orgasmic disorder. Female sexual arousal disorder is treated with estrogen replacement therapy when indicated or vaginal lubricants. The most common male sexual dysfunction disorders are premature ejaculation and erectile dysfunction. Phosphodiesterase type-5 inhibitor drugs are now the first-line treatment for erectile dysfunction, and selective serotonin reuptake inhibitors and topical anesthetic creams are nonapproved but effective treatments for premature ejaculation. Testosterone and aromatase inhibitors have been used investigationally to treat sexual dysfunction in men taking AEDs. Patient education and follow-up appointments are essential to ensure optimal outcomes of pharmacologic treatments for sexual dysfunction.
authors.affiliation: University of Southern California, School of Pharmacy, Los Angeles, CA90089-9121, USA. stimmel@usc.edu
authors.forename: Glen L
authors.initials: GL
authors.lastname: Stimmel
authors.forename: Mary A
authors.initials: MA
authors.lastname: Gutierrez
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects; D003865:Major Depressive Disorder / Q000453:epidemiology*; D004827:Epilepsy / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy* / Q000453:epidemiology*; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy* / Q000453:epidemiology*
chemical_list: D000927:Anticonvulsants; D010726:Phosphodiesterase Inhibitors